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July 23, 2013:351–6Inaccessibility to Quinidine
Therapy Is About to Get Worse
The problem of inaccessibility to quinidine, as bad as it is (1), is
likely to get worse in the near future. The problem started when
AstraZeneca discontinued its production in 2006 (2,3). Now,
a subcontractor of Sanoﬁ-Aventis, the sole producer of hy-
droquinidine, discontinued production of this valuable medica-
tion. Available supplies of hydroquinidine will reach their
expiration date by the end of this year or 2014. We are aware of
a continuous effort by Sanoﬁ-Aventis to renew the production of
hydroquinidine. However, serious shortages are likely to occur in
the near future.
Inaccessibility to alternative quinidine products is due to
limited product distribution more than limited production.
The limited number of patients in need and the low price of
the drug create a negative incentive to increase the number of
countries where quinidine is sold. Absence of established
product distribution results in requirements for special regu-
latory processes in order to get quinidine supplies on an “ad-
hoc” basis for patients in need. It is ironic that special permits
are required to prescribe quinidine in 10% of all countries (1)
even though quinidine was the most commonly prescribed
antiarrhythmic medication in these very same countries only 2
decades ago. Obtaining these special permits results in delays
of days to weeks between prescription of quinidine and actual
supply (1). Given the life-threatening and urgent nature of the
indication for the drug (arrhythmic storm with recurrent
ventricular ﬁbrillation), these waits are unacceptable. We
therefore call again on the professional medical societies to
work closely with national health care authorities to ensure
expedited access to quinidine (3,4). Speciﬁcally, this process
should consider attenuating the costs to the manufacturer to
“list” the drug with the national health regulator to ensure that
quinidine is readily and legally available in all countries,
coupled to a commitment by the manufacturer to persist with
ensuring availability and distribution of the drug.*Sami Viskin, MD
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Rhythm 2010;7:863.ReplySanoﬁ currently holds marketing authorizations for hydro-
quinidine hydrochloride prolonged-release capsules in France
since 1980 (Serecor 300 mg) and in Spain since 1973 (Lento-
quine 250 mg).
In Israel, hydroquinidine is not registered but is supplied by
Sanoﬁ via a special institutional procedure authorizing the use of
Serecor, upon request by Israeli medical institutions.
Hydroquinidine is an antiarrhythmic class IA medicine indicated
for the prophylaxis and treatment of supraventricular arrhythmias
or ventricular arrhythmias and the prevention of cardiac electric
shock in some patients carrying implantable deﬁbrillators. This
product is particularly used for preventing life-threatening
ventricular arrhythmias due to Brugada syndrome and idiopathic
ventricular ﬁbrillation.
Following the cessation of the activities of the third-party
subcontractor responsible for manufacturing the hydroquinidine
micro-granules used in Serecor prolonged release capsules, Sanoﬁ
has transferred the manufacturing process to 2 other third-party
subcontractors.
Sanoﬁ is continuously working in close cooperation with the
French Health Authorities to comply with all regulatory require-
ments, to minimize the impact of these issues on supply to market
and to maintain the availability of hydroquinidine.*Paul Chew, MD
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http://dx.doi.org/10.1016/j.jacc.2013.05.004ReplyThere is no disease so rare that it does not deserve attention.The French Brugada Association (Association du Syndrome de
Brugada) (1) was created in 2005 with the following goals: 1) to
provide up-to-date information to patients with Brugada syndrome
and their relatives; 2) to serve as a referral mechanism of patients to
specialized medical centers; and 3) to serve as an educational
authority for topics such as the risk of speciﬁc potentially harmful
medications (2). The Association also promotes improving access
to insurance for genetic carriers.
Last March we incidentally found out from a pharmacist that
it will soon be difﬁcult to ﬁnd quinidine in France. We
